Pulmonary vascular disease & thromboembolismCohort study
Prognostic Value of Tricuspid Regurgitation in Pulmonary Hypertension and Among the Different WHO Groups
- Retrospective cohort study
Authors' conclusion
Moderate or severe STR conferred mortality risk in patients with PH without left-sided valve disease or reduced left ventricular ejection fraction, beyond what can be explained by the associated RV dysfunction or impaired RV-pulmonary arterial coupling.
Study context
- Population
- Patients with PH (right ventricular (RV) systolic pressure ≥50 mm Hg on echocardiography, 2010–2023) without left-sided valve disease or reduced LVEF29% moderate or greater secondary tricuspid regurgitation (STR)
- Participants
- 1,318 patients
- Exposure
- Moderate or greater STR vs less than moderate STR
- Outcome
- All-cause mortality
- Follow-up
- Median 1.5 years (Q1-Q3: 0.3-4.6 years)
Main finding
As reported in the abstract
median 1.5 years
Deaths (all patients)
454
Observational data: associations, not effects.
Further findings
Mortality by WHO group of PH (subgroup)
- Association of moderate or severe STR with mortality remained across the individual WHO groups
Clinical profile with moderate or greater STR
- More symptomatic and congested; worse RV function and pulmonary pressures
Original publication
Prognostic Value of Tricuspid Regurgitation in Pulmonary Hypertension and Among the Different WHO Groups. JACC Cardiovasc Imaging. Published 10 June 2026. doi:10.1016/j.jcmg.2026.04.016
Summarised from the published abstract; every number is checked against it